Braidwell LP Buys 557,934 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Braidwell LP boosted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 19.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,452,447 shares of the company's stock after acquiring an additional 557,934 shares during the period. Kiniksa Pharmaceuticals accounts for 2.0% of Braidwell LP's investment portfolio, making the stock its 16th largest holding. Braidwell LP owned about 4.78% of Kiniksa Pharmaceuticals worth $68,289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas increased its holdings in Kiniksa Pharmaceuticals by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after acquiring an additional 719 shares during the last quarter. Martingale Asset Management L P increased its holdings in Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock valued at $976,000 after buying an additional 900 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares in the last quarter. Franklin Resources Inc. grew its stake in Kiniksa Pharmaceuticals by 1.7% during the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after acquiring an additional 1,100 shares in the last quarter. Finally, MetLife Investment Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after purchasing an additional 1,374 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Stock Down 2.4 %

KNSA stock traded down $0.63 during midday trading on Friday, reaching $26.09. 272,058 shares of the company's stock traded hands, compared to its average volume of 481,237. The company has a 50-day simple moving average of $22.40 and a two-hundred day simple moving average of $21.34. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -186.34 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $17.38 and a 1-year high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business's quarterly revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.25) earnings per share. Equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Wedbush reiterated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Citigroup began coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $38.80.

Insiders Place Their Bets

In other news, CFO Mark Ragosa sold 36,372 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total value of $809,277.00. Following the sale, the chief financial officer now owns 22,958 shares of the company's stock, valued at $510,815.50. The trade was a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Michael R. Megna sold 17,647 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $26.69, for a total value of $470,998.43. Following the sale, the chief accounting officer now owns 32,546 shares of the company's stock, valued at approximately $868,652.74. This trade represents a 35.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 242,768 shares of company stock worth $5,865,486 over the last three months. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.